Substantial proportions of patients with metastatic melanoma develop brain metastases during the course of their disease, often resulting in significant morbidity and death. Despite recent advances with BRAF/MEK and immune-checkpoint inhibitors in the treatment of patients who have melanoma with extracerebral metastases, patients who have melanoma brain metastases still have poor overall survival, highlighting the need for further therapy options. A deeper understanding of the molecular pathways involved in the development of melanoma brain metastases is required to develop more brain-specific therapies. Here, the authors summarize the currently known preclinical data and describe steps involved in the development of melanoma brain metastases. Only by knowing the molecular background is it possible to design new therapeutic agents that can be used to improve the outcome of patients with melanoma brain metastases.
INTRODUCTION
Melanoma has the highest propensity for the development of brain metastasis among all solid tumors. Previous studies revealed that up to 44% of all patients with stage IV melanoma develop brain metastases, and 75% of patients have central nervous system (CNS) involvement identified at autopsy. 1 Furthermore, significant risk of hemorrhage 2 and edema can lead not only to death but also to debilitating morbidity, including poor quality of life and neurocognitive decline. 3 Thus, therapies directed at melanoma brain metastasis (MBM) not only should improve outcome but also should enhance quality of life. Until recently, patients with active MBM were excluded from most clinical trials, but there is a significant and pressing need for the inclusion of these patients to develop better therapy options.
CURRENT TREATMENT OPTIONS FOR PATIENTS WITH MBM
Several treatment options are currently available for patients with MBM and have been described in great detail in recent reviews. [4] [5] [6] These options include focal approaches like surgery and radiotherapy and systemic therapies, such as targeted therapy and immunotherapy; the latter options have become significantly more important over the last few years.
Local Therapies
Before the era of targeted therapy and checkpoint inhibitors, surgical resection and radiotherapy were the main treatment options for patients with MBM. 7 Surgery remains the gold standard for patients with a solitary and symptomatic brain lesion and can lead to rapid control. 8, 9 Often, patients receive postsurgical radiotherapy to decrease the risk of local recurrence. 10, 11 Because stereotactic radiosurgery (SRS) can lead to high and durable intracranial control rates, 12, 13 it has replaced whole-brain radiotherapy (WBRT) as a new standard treatment option for patients who have from 1 to 3 brain metastases measuring up to 3 cm in greatest dimension. 4 Modern radiation techniques include the use of gamma knife SRS, linear accelerators, and proton therapy to specifically radiate brain lesions without affecting the surrounding brain tissue, thus causing fewer side effects than WBRT.
Systemic Therapies

Chemotherapy
Temozolomide and fotemustine traditionally have been used in patients with MBM. However, despite central nervous system penetration, these agents have demonstrated only limited antimelanoma activity in the brain. 15, 16 Targeted therapies About 40% to 50% of melanomas contain a mutation in B-raf proto-oncogene serine/threonine kinase (BRAF), the most frequent of which are BRAF valine-to-glutamic acid, valine-to-lysine, and valine-to-aspartic acid substitutions at codon 600 (V600E, V600K, and V600D, respectively). 17 These mutations lead to a constitutively activated mitogenactivated protein kinase (MAPK) signaling pathway and thereby to enhanced cell growth and survival. 17 The impressive antitumor activity of BRAF inhibitors like vemurafenib and dabrafenib in patients with BRAFmutated, metastatic melanoma led to their regulatory approval and to further investigations of their efficacy in MBM. In a phase 2 trial, 39.2% of patients with MBM who had not received previous therapy and 30.8% of those who had MBM and had received previous local treatment responded to dabrafenib. 18 A pilot study using vemurafenib in patients with symptomatic MBM demonstrated that 7 of 19 patients with measurable intracranial disease had >30% intracranial tumor regression. 19 The median progression-free survival in that trial was 3.9 months, and the median overall survival was 5.3 months, which was shorter than that observed in patients without MBM who received treatment with BRAF inhibitors, suggesting a brain-specific resistance mechanism (see below). 19 Small-molecule inhibitors like trametinib, cobimetinib, and binimetinib, which target the downstream effector molecule of BRAF, MEK (mitogen-activated protein kinase kinase), are now routinely used in combination with BRAF inhibitors and have significantly improved the survival of patients with metastatic melanoma compared with monotherapy and prolonged the time until patients developed resistance. 20, 21 On the basis of these observations, increasing numbers of trials using combined BRAF and MEK inhibition are being launched for patients with MBM, and additional studies are evaluating the safety and efficacy of combining targeted therapy with SRS (Table 1) .
Finally, the phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/AKT) pathway appears to play a fundamental role in the survival and growth of melanoma cells in the brain microenvironment, 22, 23 suggesting that PI3K inhibitors may be a potential therapeutic approach for patients with MBM. Currently, a phase 2 trial is investigating the effect of the PI3K inhibitor buparlisib in patients with MBM (Table 1) .
Immunotherapies
Antibodies against cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1), known as checkpoint inhibitors, are important in regulating immune responses and have revolutionized the treatment of patients with metastatic melanoma and other cancers. 24 Like targeted therapies, trials testing these new agents have excluded patients with MBM. An initial study using the anti-CTLA-4 antibody ipilimumab had activity in patients who had asymptomatic MBM, producing an Post-op, postoperative; V600E, valine to glutamic acid substitution at codon 600.
intracranial disease control rate of 24%, whereas the disease control rate was only 10% for patients who had symptomatic MBM. 25 Early results of an ongoing phase 2 trial with the anti-PD-1 antibody pembrolizumab indicated an intracranial overall response rate of 22% in 22 MBM patients (NCT02085070) ( Table 2) . 26 Multiple retrospective analyses have also examined the efficacy and safety of combining checkpoint inhibitors with radiotherapy. One study reported a median survival of 21.3 months in patients who underwent SRS and received ipilimumab; and, in another study, significantly improved outcomes were observed in patients who received radiotherapy and an anti-CTLA-4 antibody. 27, 28 In contrast, several other studies could not confirm a clinical benefit for patients with MBM who received radiotherapy combined with ipilimumab compared with those who received radiotherapy alone. 29, 30 A retrospective analysis demonstrated that SRS was well tolerated in 25 patients who received nivolumab, 31 with only 1 patient developing grade 2 side effects. Prospective trials to evaluate the safety and efficacy of combination treatments (Table 2) are needed, and it remains to be determined whether radiotherapy combined with anti-PD-1 therapy will be superior to therapy with anti-CTLA-4. Finally, other studies evaluating the combination of anti-CTLA-4 and anti-PD-1 therapies without the concomitant use of radiotherapy (Table 2 ) are currently ongoing.
Although these initial results are promising, outcomes for patients with MBM remain poor. This may be for multiple reasons. Patients with symptomatic MBM require treatment with steroids, which can decrease the response to immunotherapy. 25 In addition, MBM that are resistant to targeted agents may develop during the treatment of extracerebral metastases. Although new combination studies designed to further improve the efficacy of these drugs are on their way (Tables 1 and 2) , there remains an urgent need to generate more brain-specific therapies.
MOLECULAR DETERMINANTS OF MBM
Similar processes, such as attachment of melanoma cells to the endothelial cells of the organ vasculature, extravasation, and colonization, are required for metastases formation in the brain and extracerebral sites. However, the brain has been regarded as a "sanctuary site," exhibiting a bloodbrain barrier (BBB) with tight junctions that restrict the passage of macromolecules. In addition, the brain exhibits different immune responses than other organs, suggesting that the formation of metastases in the brain may require different or additional steps compared with the formation of metastases in other parts of the body.
To gain more insight into human MBM formation, different murine models have been used, including the injection of human melanoma cells directly into the carotid artery, cardiac ventricle, or the brain parenchyma or generating special mouse models that develop spontaneous brain metastases. 4, 6 A microscopic glimpse of how melanoma cells enter and colonize the brain was provided by Kienast et al. 32 Red fluorescent protein-tagged lung cancer and melanoma cells were injected into the internal carotid artery of nude mice and were followed by real-time, multiphoton laser-scanning microscopy. Melanoma cells circulated in the brain vasculature and arrested in microvessels and branch points because of size restrictions. After extravasation, melanoma cells remained in close and persistent contact with the brain vasculature and used those vessels as tracks for invasion of the brain (vessel cooption). Cells that did not have any contact with microvessels quickly regressed. In contrast to lung metastases, melanoma proliferation to macrometastases involved vascular remodeling and loop formation without the induction of early sprouting angiogenesis (summarized in Fig. 1 ). At each step of this metastatic cascade, melanoma cells have to tackle the brain defensive mechanisms, adapt to the brain microenvironment, and even use it for their advantage. Each of these steps is discussed in the following paragraphs, which elucidate how melanoma cells: 1) facilitate BBB penetration; 2) hijack the brain vascular system for supply of nutrients and oxygen; 3) interact with brain cells, such as astrocytes, for protection against apoptosis and for assistance in tumor proliferation; and 4) avoid the immune system by suppressing macrophage and T-cell responses.
Transmigration Through the BBB
BBB composition and permeability
The BBB protects the brain by restricting the entrance of large lipophilic macromolecules from the vasculature system into the parenchyma. It consists of endothelial cells, extracellular matrix (ECM), pericytes, and astrocytes, all of which participate in the passive diffusion of water and gases and the active transportation of glucose and essential amino acids (Fig. 2) . Endothelial cells line the vasculature systems and contain different transporters in their membrane. They are connected through tight junctions that are composed of transmembrane proteins, such as occludin and claudin, and cytosolic zonula occludens proteins. 33 An uninterrupted BBB prevents the entry of most therapeutic agents from the blood stream into the brain Figure 1 . This is a schematic representation of melanoma cell invasion and metastasis formation in the brain. When circulating melanoma cells reach the brain vasculature system, they arrest at blood vessel branch points, allowing attachment to the endothelial cells. Melanoma cells then transmigrate through the endothelial cell layer into the brain by disrupting the tight junctions and degrading the extracellular matrix (ECM) proteins (see blood-brain barrier representation in Fig. 2 ). Once in the brain parenchyma, melanoma cells prefer vessel cooption and stay close to the existing brain vasculature. The growth from micrometastases to macrometastases is influenced by the brain microenvironment, especially by resident astrocytes and microglia and infiltrated T cells. At later stages, melanoma growth may involve neoangiogenesis at the tumor margin. The melanoma genes and proteins involved at each stage are listed at the bottom of the figure. ADAMTS1 indicates ADAM metallopeptidase with thrombospondin type 1 motif 1; AKT1, AKT serine/threonine kinase 1; ANGPT2, angiopoietin 2; bFGF, basic fibroblast growth factor; CCR4, C-C motif chemokine receptor 4; EDNRB, endothelin receptor type B; HPSE, heparanase; MMP-2, matrix metalloproteinase 2; MTF, melanotransferrin; NT receptor, neurotransmitter receptor; PD-L1, programmed death 1 ligand; PI3K/AKT, phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B; PLEKHA5, pleckstrin homology domain containing A5; PTEN, phosphatase and tensin homolog; SERPINF1, serpine family E member 1; TGF-b2, transforming growth factor b2;VEGF, vascular endothelial growth factor; VEGF-A, vascular endothelial growth factor A.
parenchyma. However, increased permeation of the BBB has been observed in animal models with MBM greater than 0.2 mm 2 . 34 Despite this, the efficacy of chemotherapeutic agents on larger MBM remains low, and BRAF inhibitors like vemurafenib are more active on extracerebral than cerebral melanoma metastases. 15, 16, 35 This may be caused by an inability to achieve the same therapeutic drug levels in the brain as in extracerebral sites, which has been attributed to efflux transporters in the endothelial membrane. These transporters function by pumping macromolecules back into the blood stream, thus decreasing drug concentration in the brain parenchyma. Many cytotoxic and targeted agents, such as vemurafenib, dabrafenib, trametinib, or omipalisib (a phosphatidylinositol-3-kinase/mammalian target of rapamycin [PI3K/mTOR] inhibitor), are substrates of these efflux transporters. [36] [37] [38] [39] [40] Therefore, it is of great importance to use highly active drugs that either naturally penetrate the brain 41 or are specially designed to cross the BBB 42 or perhaps to use the current therapeutic agents in combination with efflux transporter inhibitors. 38, 40 
BBB penetration
To reach the brain, circulating melanoma cells have to actively cross the BBB. In an in vitro model, Fazakas et al provided evidence that melanoma cells thereby used the paracellular pathway. 43 The process of penetration started with melanoma cells adhering to the endothelial cells. The cells then squeezed between the endothelial cells, accompanied by disruption of the tight junction transmembrane proteins occludin and claudin-5 and the cytoplasmic zonula occludens-1 protein.
Proteins that facilitate BBB penetration have been studied extensively in brain metastases of lung and breast cancers and are involved in adhesion, cell-cell contact, cytoskeleton remodeling, angiogenesis, proteolysis, and chemokine signaling. 44 Melanoma cells have developed similar but also unique strategies to cross the BBB (Fig. 1) .
Integrins are a family of adhesion receptors, thus influencing cell attachment and angiogenesis and promoting invasion and migration of tumor cells. 45, 46 Integrin a m b3 expression was increased in brain metastases versus primary tumors from a variety of cancers, including melanoma, 47 thus representing an interesting drug target. The monoclonal antibody against a m intergrins, cilengitide (Merck KGaA, Darmstadt, Germany), was used successfully in glioblastoma 48 but had only minimal clinical efficacy as a monotherapy in metastatic melanoma. 49 Further studies are therefore necessary to determine whether MBM can be targeted through integrin inhibition.
That the adhesion of melanoma cells to brain endothelial cells is crucial in the early process of transmigration was demonstrated in a different study, in which PI3K and Ras-related C3 botulinum toxin substrate (RAC) inhibitors prevented both of these actions. 50 It also was demonstrated that the melanoma antigen melanotransferrin (MTF) played a role in the development of brain metastases as an antibody against MTF and decreased the formation of brain metastases in MTF-positive melanoma cells injected intravenously. determine whether this antibody could be deployed in a clinical setting.
Jilaveanu et al observed that expression of pleckstrin homology domain containing A5 (PLEKHA5) in primary tumors correlated with early development of MBM. In vitro silencing of PLEKHA5 resulted in reduced ability of melanoma cells to cross the BBB, suggesting that PLE-KHA5 is important for the transmigration process. 52 Melanoma cells express neurotrophin receptors with a high affinity to brain-derived neurotrophins, suggesting that the latter factors may play a role in recruiting melanoma cells to the brain. 53, 54 After the binding of neurotrophins to their receptors, the ECM-degrading enzyme heparanase (HPSE) was up-regulated in melanoma cells. 55 The action of HPSE leads to the release of growth factors, chemokines, and angiogenic factors from the ECM and is important for the extravasation of metastatic melanoma. 56 In an in vivo brain-slice model, high levels of HPSE led to increased melanoma brain invasion. 57 Various inhibitory molecules that target HPSE have been developed, including neutralizing antibodies and smallmolecule inhibitors, 56 and could be used as drugs against MBM. In line with this, different micro-RNAs targeting HPSE reduced the invasion and migration properties of metastatic melanoma in vivo and suppressed the formation of breast cancer brain metastases in vitro. 57, 58 The serine protease separase enabled BBB penetration of melanoma cells through disintegration of tight junctions, which was markedly reduced by the protease inhibitor Pefabloc (Sigma-Aldrich, St Louis, Mo). 43 Increased ECM-degrading proteins, such as the matrix metalloproteinase 2 (MMP-2), have been correlated with increased BBB penetration in melanoma cells. 59 In addition, an enhancement of melanoma migration was observed after MMP-2 induction in these cells by astrocyte-secreted factors, such as interleukin-23 (IL-23). 60 MMP-2 was also produced upon up-regulation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway in MBM of brain trophic melanoma cells compared with parental melanoma lines, leading to increased cell invasion and angiogenesis. 61, 62 In addition to MMP-2, expression levels of basic fibroblast factor (bFGF) and vascular endothelial growth factor (VEGF) also were increased after STAT3 activation in these brain-trophic melanoma cells. 62 Collectively, these data suggest that the JAK/STAT pathway could be targeted in MBM. Indeed, the first preclinical data from the brain-permeable STAT3 signaling inhibitor WP1066 alone or in combination with cyclophosphamide indicated antitumor activity in brain metastatic melanoma. 63, 64 WP1066 is now in clinical trials for MBM (NCT01904123).
Postextravasation and growth to micrometastases and macrometastases
In the study by Kienast and colleagues, it took 3 to 14 days for the extravasation process. 32 The cells then underwent a phase of dormancy, which was followed by an outgrowth to micrometastases and macrometastases 32 ( Fig.  1) . In both patient and mouse models, MBM were identified at different sites within the brain, such as the brain parenchyma and the (lepto)-meninges. 1, 65, 66 One molecular determinant for this site specificity was identified as the expression level of transforming growth factor-b2 (TGF-b2) in tumor cells. 67 Simonsen et al noted that melanoma cells growing in meninges and ventricles were highly angiogenic, whereas the same cells growing in the brain parenchyma stayed close to the existing vasculature (vessel cooption) without inducing neoangiogenesis, despite expression of the angiogenic factors VEGF-A and IL-8. 65 In other studies, however, induction of angiogenesis occurred when VEGF-A was overexpressed in the melanoma cells. [68] [69] [70] MBM produced by brain-trophic melanoma cells were highly vascularized and had increased expression of bFGF, VEGF, and MMP-2. 62 Conversely, growth of melanoma cells in the brain parenchyma by vessel cooption without angiogenesis was observed in many mouse models of MBM 32, 42, 71, 72 and in tissue sections of human brain metastases. 32, 71, 73 Melanoma cells may establish this "perivascular niche" to use the vascular system for invasion of the brain parenchyma, to be supported with sufficient nutrients from the blood vessels, and to be protected from immune and stress responses.
During growth to larger macrometastases, when vessel density further decreases and availability of nutrients diminishes, neoangiogenesis may become necessary for melanoma survival. In a glioma brain model, tumors started off with vessel cooption and active vessel regression at the tumor center, accompanied by expression of the angiogenesis inhibitor angiopoietin 2 (ANGPT2), but changed to induction of angiogenesis at the tumor margin because of increased VEGF-A expression. 74 A similar vasculature pattern was also observed in a melanoma mouse model, 75 indicating that similar processes may be involved in MBM formation.
There is no doubt that secretion of angiogenic factors, such as placental growth factor 1 (PGF-1), VEGF-A, FGF-2, IL-8, and TGF-1, and induction of neoangiogenesis by melanoma cells are important during the early stages of melanoma transformation and metastasis at extracerebral sites. 76 However, as discussed above, the role of neoangiogenesis and the involvement of VEGF-A during colonization of melanoma cells in the brain seem to be a lot more complex. 37, 77 Thus, treatment of melanoma cell lines in vitro and MBM in vivo with antiangiogenesis drugs have yielded varying results. 69, 78 The VEGF-A inhibitor bevacizumab is now being used in combination with pembrolizumab to control for cerebral edema in patients with MBM (clinicaltrials.gov identifier NCT02681549).
A recent study profiled angiogenesis-related genes in human brain metastases, including melanoma. 79 Although the study identified angiogenesis-related genes that had increased expression in all cancer groups, genes involved in the degradation of the ECM (MMP-2, ADAMTS1) and antiangiogenic factors (SERPINF1 and ANGPT2) were uniquely up-regulated in melanoma, indicating that angiogenesis induced by melanoma may differ from that of other brain metastases.
Carbonell and colleagues noted that adhesion of metastatic cells through integrins to the brain vascular basement membrane promotes vascular cooption and early tumor growth. 71 Integrins are also overexpressed in MBM, as described above, 47 indicating a role for these proteins in blood vessel attachment and cooption during melanoma colonization in the brain parenchyma.
Inhibition of blood vessel cooption and extravasation of melanoma cells was achieved using an inhibitor of the gap junction protein Connexin26, 80 providing another clue of how melanoma cells contact the vasculature system to initiate metastases formation in the brain.
Interaction of Melanoma Cells With the Brain Microenvironment
During proliferation to macrometastases, melanoma cells come into contact with different brain cells that have either tumor-suppressive or tumor-promoting functions (Fig. 1) .
Astrocytes
Astrocytes are vital for homeostasis, provide support to endothelial cells and neurons, and support repair of brain tissue after injuries by secreting various growth factors and cytokines or by directly interacting with other brain cells. 81 Breast cancer and lung cancer cells use astrocytes for their advantage and promote the release of astrocytic inflammatory cytokines, such as IL-1, IL-6 and tumor necrosis factor a (TNF-a), to proliferate in the brain. 82, 83 In melanoma, astrocytes promote invasion and transmigration of the tumor cells by releasing neurotrophins, heparanase, and IL-23. 60, 84, 85 Another study demonstrated that soluble factors from astrocyte-conditioned medium up-regulate the PI3K/AKT pathway in melanoma cell lines. 86 In addition, astrocytes can epigenetically downregulate phosphatase and tensin homolog (PTEN), an inhibitor of the PI3K/AKT pathway, leading to enhanced tumor proliferation of breast cancer and melanoma metastases in the brain. 87 The up-regulation of survival genes like GSTA5, Bcl2L1, and TWIST1 and a resistance to chemotherapeutic drugs of lung and breast cancer cells appear to be caused by direct contact through gap junctions between astrocytes and tumor cells. 88 A similar interaction leading to resistance to chemotherapeutic drugs was also observed in cocultures of melanoma cells and astrocytes. 89 
Microglia
Microglia are sessile macrophages and main effector cells of the innate immune system in the brain. 90 Tumorsuppressive functions include the induction of cytotoxicity through nitric oxide release, phagocytosis of tumor cells, and activation of tumor-specific B cells and T cells. However, these cells also exhibit tumor-promoting functions by expressing PD-L1 ligand (PD-L1) on their surface, leading to inhibition of cytotoxic T cells. 91 Furthermore, it has been demonstrated that microglia secrete various growth factors and cytokines that promote primary brain tumor growth and invasion, 92 suggesting that these factors also support the growth of brain metastases. By using confocal imaging of an organotypic brain slice culture model, Pukrop et al observed that microglia were attracted to the breast cancer tumor front and actively prepared the way for invasion and colonization of the brain. 93 It was also demonstrated that this was Wntsignaling pathway-dependent, because a Wnt-inhibitor abolished the process. It remains to be determined whether microglia promote MBM in a similar manner.
Tumor-associated macrophages
Another cell type that is associated with primary brain tumors like gliomas are the tumor-associated macrophages (TAMs). 94 It is difficult to determine whether these macrophages are in fact brain-naive microglia or originally derived from the blood, but they are likely to be a mixture of both. 94 Like microglia, TAMs are attracted by factors released from the brain tumor. Activated TAMs possess a tumor-suppressive M1 phenotype that secrets proinflammatory TNF-a or IL-1b. However, TAMs also have a tumor-promoting M2 phenotype. By secreting VEGF, IL-10, and TGF-b, M2 TAMs promote growth and invasion of gliomas through ECM remodeling, angiogenesis, and stimulation of immunosuppressive T cells, as reviewed by Hambardzumyan et al 94 and Hamilton and Sibson. 95 Multiple therapeutic approaches against the tumor-promoting influence of microglia and TAMs are currently being explored in gliomas, 94 but their benefit in the treatment of MBM remains to be determined. In metastatic brain tumors, including melanoma, Tcell infiltration varies vastly between patients; however, in patients with high infiltration, different subtypes of T cells have been observed. 96, 97 Infiltrated T cells were identified around the vasculature structures and at the tumor margin, but seldom in the tumor center. A high density of CD3-positive, CD8-positive, and CD45RO-positive T cells in the brain appeared to be associated with improved overall survival for those patients compared with patients who had low intracranial T-cell density. 96 Other studies reported a similar association of improved survival with increased T-cell infiltration in patients with brain metastases. 98, 99 It is noteworthy that lower T-cell infiltration in the brain and skin has been described compared with that in other metastatic sites of melanoma. 99 Tumor cells develop different mechanisms to evade the immune system. In metastatic melanoma, the lack of T-cell infiltration observed in some patients was caused by tumor-intrinsic b-catenin activation, resulting in decreased dendritic cells and thus T-cell recruitment. 100 Another study demonstrated that areas of metastatic melanoma cells with decreased PTEN and increased VEGF-A expression correlated with decreased T-cell infiltration. 101 The use of anti-VEGF antibody enhanced T-cell infiltration into those areas and improved antitumor activity. Whether these mechanisms of immune evasion are also present in MBM still needs to be investigated.
Hijacking the peripheral immune tolerance mechanism presents another mechanism by which brain tumor cells inhibit the immune system. For instance, primary tumors like glioblastoma exhibit hardly any immune reaction because of the expression of PD-L1 and other immunosuppressive molecules, such as IDO and TGF-b. 91, 102 Expression of PD-L1 was also observed in MBM and was associated with higher T-cell infiltration. 97 The presence of PD-L1-expressing melanoma cells in the brain suggests that immunotherapy with anti-CTLA-4 and PD-1 antibodies should be successful in patients with MBM who have infiltration of cytotoxic T cells. Ipilimumab and pembrolizumab had some effects in patients with MBM, as detailed above (see Immunotherapies). 25, 26 Perhaps this could be increased with improved biomarker screening and appropriate combination therapies.
How Do Melanoma Metastases Adapt to the Brain Environment?
To adapt to the brain microenvironment, melanoma cells undergo changes in their DNA, protein expression, and epigenetic profile. Whether these changes are already present in the primary tumor promoting recruitment to the brain or whether these changes only arise when confronted with the brain microenvironment remains to be determined. A study of 86 patients with renal cell carcinoma, lung and breast cancer brain metastases revealed that the brain and matching primary tumors are often genetically different, with frequent alterations in CDKN2A and HER2/EGFR genes and in genes of the PI3K/AKT pathway. 103 Conversely, in squamous cell lung cancer, primary tumors and brain metastases shared loss of the PI3K/ AKT inhibitor PTEN, 104 suggesting that adaptation to the brain may require a bit of both changes early on in the primary tumor as well as changes acquired during the metastatic process.
Mutations in primary tumor prime melanoma for brain metastases
The hypothesis that the high incidence of MBM is because melanocytes and neuronal populations share common progenitors 105 has long been used to support the idea that melanoma primary tumors may already possess characteristics that prime them for brain metastases formation. Detailed studies comparing melanoma primary tumors, extracerebral metastases, and cerebral metastases have not been performed to date. However, the study by Chen and colleagues indicated no differences in hotspot mutations or copy-number variations in matched pairs of brain and extracerebral melanoma metastases. 22 Other studies noted that primary melanoma tumors expressing PLEKHA5 or MTFpositive melanoma cells exhibited increased development of brain metastases. 51, 52 In addition, patients with diagnosed stage IV disease had a higher risk of developing MBM when carrying a BRAF or NRAS mutation compared with those carrying the wild-type genes. 106 These data indicate that mutations in the primary tumor can indeed contribute to the colonization of melanoma metastases in the brain.
Brain-derived factors lure melanoma cells to the brain
Another hypothesis has been derived from the Paget "seed-and-soil" hypothesis, 107 in that brain-derived soluble factors, such as chemokines, promote migration of melanoma cells to the brain. For instance, C-C motif chemokine receptor 4 (CCR4) is expressed higher on melanoma cells in the brain compared with melanoma cells at other metastatic sites. Brain-derived factors up-regulated CCR4 in melanoma cell lines and enhanced their migration to the brain. 108, 109 Another study supported these data and indicated that cerebrospinal fluid from patients with melanoma, compared with healthy controls, exhibited an altered expression of CCR4 ligands like CCL4 and CCL22. 110 
Overexpression of proteins in melanoma cells residing in the brain
There is much evidence that protein expression levels are altered when melanoma cells interact with the brain microenvironment. In a model of spontaneous MBM, Cruz-Munoz et al observed increased expression of the endothelin receptor B (EDNRB). 111 EDNRB facilitates migration and proliferation of melanocytes and has been proposed to promote melanoma progression when overexpressed. 112 Although overexpression of EDNRB elevated the overall metastatic potential, it also increased the incidence of brain metastases. 111 In addition, EDNRB inhibitors improved the median survival of mice and decreased cerebral metastases when combined with the efflux transporter inhibitor cyclosporin A. BQ788, an EDNRB antagonist, was well tolerated and reduced the viability of melanoma cells in clinical trials for melanoma skin metastases, 113 indicating its potential as a therapeutic drug for MBM. Activation of the JAK/STAT pathway and overexpression of integrin a m b3 was observed in MBM compared with their primary counterparts, as mentioned above. 47, 61, 62 The PI3K/AKT pathway reportedly is up-regulated in MBM. The first report was provided by Davies and colleagues, who demonstrated increased phosphorylated AKT (pAKT) and lower PTEN levels in MBM compared with liver and lung metastases. 114 By comparing brain and extracerebral melanoma metastases from the same patient, Niessner et al observed overexpression of pAKT in MBM from all patients tested. 86 In accordance with this finding, a reverse-phase protein array of matched brain and extracerebral melanoma metastases detected increased expression of several proteins of the PI3K/AKT pathway only in the brain metastases. 22 Complete loss of PTEN was associated with a shorter time to MBM development. 115 In addition, development of MBM was observed in 80% of mice when AKT1 was overexpressed and PTEN was silenced. 116 Because the PI3K/AKT pathway appears to play a major role in the development of brain metastasis, targeting this pathway has been the focus of extensive research efforts in the last couple of years. Niessner et al reported that PI3K inhibition led to growth inhibition of melanoma cell lines in vitro and of MBM in vivo.
23 PI3K inhibitors also overcame cerebrospinal fluid-induced resistance to BRAF inhibitors in MBM. 117 The early phase of transmigration of melanoma cells to the brain was also inhibited using a PI3K inhibitor. 50 Osswald et al used a BBBpermeable PI3K/mTOR inhibitor to induce apoptosis of MBM. 42 Taken together, it is not surprising that different inhibitors of the PI3K/AKT pathway are being investigated in clinical trials for metastatic melanoma, including MBM, such as buparlisib (PI3K inhibitor, NCT02452294), perifosine (AKT inhibitor, NCT00053781), MK2206 (AKT inhibitor, NCT01480154), GSK2141795 (AKT inhibitor, NCT01941927), everolimus (mTOR inhibitor, NCT00098553), temsirolimus (mTOR inhibitor, NCT00397982), and UCN-01 (PDK1 inhibitor, NCT00072189).
Epigenetic regulation of MBM
How these differences in protein expression levels of the brain versus extracerebral metastases and primary tumors arise is still unknown, but early evidence suggests that epigenetic regulation may play a major role. Micro-RNA that is secreted in extracellular vesicles by astrocytes transiently down-regulates PTEN in breast cancer and melanoma cell lines, as previously noted. 87 Transmitting proteins, lipids, and nucleic acids through exosomes is a process being used by many cell types for cell-cell communication. 118 Cancer cells use this communication pathway to manipulate their tumor microenvironment, making exosomes and their contents attractive targets in the search for novel cancer biomarkers. 118 The microRNA-146a
reportedly was absent in brain-trophic melanoma cells compared with the parental cell line, 119 indicating that down-regulation instead of up-regulation of microRNA can also cause MBM.
In an extensive microarray study of lung, breast, and melanoma xenografts at different metastatic sites, Park and colleagues observed epigenetically regulated transcriptional reprogramming of tumor cells in the brain to a more neuronal phenotype that was partly induced by astrocytes. 120 Similar results were reported by Nygaard et al, who observed a neuron-like phenotype of melanoma cells implanted into the brain, especially in the early phase of metastatic growth. 121 The acquisition of a neuronal phenotype of tumor cells because of transcriptional changes may be another mechanism of immune evasion.
CONCLUSIONS
Significant clinical advances have been made in recent years in the treatment of patients with MBM. Only a decade ago, patients with MBM had limited treatment options, and little hope of prolonged overall survival. Today, different therapy options are available, including surgery, radiotherapy, and various combinations of targeted and immunotherapy. Nevertheless, it has become clear that the same therapies that work very well on extracerebral melanoma metastases have a lesser impact on metastases of the brain. The search for effective, brain-specific therapies is now the focus of many scientists and clinicians. Different parameters from the tumor as well as the brain microenvironment contribute to invasion and colonization of melanoma cells in the brain and resistance to current therapies. Some of these candidate mechanisms have already been targeted therapeutically with promising results. We are now eagerly awaiting a new line of therapies that specifically and effectively target MBM.
FUNDING SUPPORT
No specific funding was disclosed.
